NCT03354429

THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death

A Randomised, Double-Blind, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared With ASA in the Prevention of Stroke and Death in Patients With Acute Ischaemic Stroke or Transient Ischaemic Attack

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 11,016 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 40 Years – 130 Years
• Healthy volunteers: Not accepted

Summary

Study to investigate if the study drug ticagrelor and ASA is more effective than Placebo (inactive tablet) and ASA in preventing new stroke events

Conditions

• Acute Ischaemic Stroke
• Transient Ischaemic Attack

Interventions

Type	Name	Description
DRUG	Ticagrelor	Ticagrelor arm: Day 1, loading dose of ticagrelor followed by daily maintenance dose until Day 30.
DRUG	Placebo	Placebo arm: Day 1, loading dose of placebo followed by placebo daily maintenance dose until Day 30.

Timeline

• Start date: 2018-01-22
• Primary completion: 2019-12-13
• Completion: 2019-12-13
• First posted: 2017-11-28
• Last updated: 2020-12-22
• Results posted: 2020-12-22

Locations

387 sites across 28 countries: Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Czechia, France, Germany, Hong Kong, Hungary, India, Italy, Mexico, Peru, Poland, Romania, Russia, Saudi Arabia, Slovakia, South Korea, Spain, Sweden, Taiwan, Thailand, Ukraine, Vietnam